# Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma

> **NCT04435977** · PHASE2 · UNKNOWN · sponsor: **Istituto Clinico Humanitas** · enrollment: 46 (estimated)

## Conditions studied

- Hepatocarcinoma

## Interventions

- **DRUG:** Cabozantinib 60 MG

## Key facts

- **NCT ID:** NCT04435977
- **Lead sponsor:** Istituto Clinico Humanitas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-30
- **Primary completion:** 2023-06
- **Final completion:** 2023-09
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2020-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04435977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04435977, "Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04435977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*